These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 13227010)
41. Anion exchanger 2 mediates the action of arsenic trioxide. Pan XY; Chen GQ; Cai L; Buscemi S; Fu GH Br J Haematol; 2006 Sep; 134(5):491-9. PubMed ID: 17018029 [TBL] [Abstract][Full Text] [Related]
42. Osteomyelitis due to arsenic trioxide use for tooth devitalization. Dumlu A; Yalcinkaya S; Olgac V; Güvercin M Int Endod J; 2007 Apr; 40(4):317-22. PubMed ID: 17298410 [TBL] [Abstract][Full Text] [Related]
43. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Sanz MA; Fenaux P; Lo Coco F; Haematologica; 2005 Sep; 90(9):1231-5. PubMed ID: 16154847 [TBL] [Abstract][Full Text] [Related]
44. [Anti-hepatoma effect of arsenic trioxide on rat liver cancers induced by 2-acetamidofluorene]. Huang JF; Tan B; Wei Q; Zhang H; Ni RZ Zhonghua Gan Zang Bing Za Zhi; 2005 Aug; 13(8):623-5. PubMed ID: 16093000 [No Abstract] [Full Text] [Related]
45. Arsenic trioxide consolidation in APL. Das M Lancet Oncol; 2017 Sep; 18(9):e517. PubMed ID: 28803794 [No Abstract] [Full Text] [Related]
46. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia. Ducas RA; Seftel MD; Ducas J; Seifer C J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914 [TBL] [Abstract][Full Text] [Related]
47. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700 [TBL] [Abstract][Full Text] [Related]
48. [Antitumor effect of arsenic trioxide on mice experimental liver cancer]. Chen H; Qin S; Pan Q Zhonghua Gan Zang Bing Za Zhi; 2000 Feb; 8(1):27-9. PubMed ID: 10712780 [TBL] [Abstract][Full Text] [Related]
49. Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. Piao W; Chau D; Yue LM; Kwong YL; Tse E Leukemia; 2017 Feb; 31(2):522-526. PubMed ID: 27795556 [No Abstract] [Full Text] [Related]
50. Herpes zoster during treatment with arsenic trioxide. Lanska DJ Ann Hematol; 2004 Jun; 83(6):408. PubMed ID: 15034759 [No Abstract] [Full Text] [Related]
51. [An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid]. Zhang X; Yang L; Qiao Z Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):113-5. PubMed ID: 11798639 [TBL] [Abstract][Full Text] [Related]
52. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646 [TBL] [Abstract][Full Text] [Related]
53. microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma. Zhu C; Zhou R; Zhou Q; Chang Y; Jiang M Life Sci; 2016 Dec; 166():34-40. PubMed ID: 27717846 [TBL] [Abstract][Full Text] [Related]
54. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia]. Lengfelder E; Schultheis B; Büchner T; Hehlmann R Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223 [No Abstract] [Full Text] [Related]